Evidence map›Paper›PMID 42473667›Full record

ArticleiScience2026

A rapid point-of-care test for vancomycin monitoring at the clinical bedside.

Damon T Burrow, David S Kinnamon, Jason Liu, Jacob T Heggestad, Simone Wall, Brooke E Silverstein, Suhail K Mithani, Vijay Krishnamoorthy, Richard Drew, Daniel Y Joh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Damon T BurrowDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
David S KinnamonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Jason LiuDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Jacob T HeggestadDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Simone WallDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Brooke E SilversteinDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Suhail K MithaniDivision of Plastic, Maxillofacial, & Oral Surgery, Duke University, Durham, NC 27708, USA.
Vijay KrishnamoorthyDepartment of Population Health Sciences, Duke University School of Medicine, Durhan, NC 27708, USA.
Richard DrewDepartment of Infectious Diseases, Duke University School of Medicine, Durham, NC 27708, USA.
Daniel Y JohDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Angus HucknallDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Ashutosh ChilkotiDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.

Funding

A Fully Integrated Point-of-Care Test for EbolaR01AI150888 · NIAID · DUKE UNIVERSITY · PI CHILKOTI, ASHUTOSH · 2020 to 2024
$3.4M
NIAID NIH HHS R01 AI150888
6 · The paper itself

Abstract

Vancomycin requires individualized dosing guided by therapeutic drug monitoring, but current laboratory assays are slow and centralized. We describe a competition-format microarray assay on a poly(oligo(ethylene glycol) methacrylate-co-glycidyl methacrylate) brush integrated into a single-use microfluidic cassette and portable reader to quantify vancomycin directly from fingerstick volumes of whole blood in 30 min. The assay shows a limit of detection of 0.8 μg/mL and precise quantification across the clinical range, with relative error below 20%. In a pilot study of 31 patient samples, cassette measurements correlated strongly with routine hospital testing with minimal bias, including when operated by minimally trained coordinators. This work establishes an approach for rapid, decentralized vancomycin monitoring that could support area-under-the-curve-based dosing in settings where access to high-complexity laboratories is limited and suggests a path toward extending therapeutic drug monitoring to point-of-care devices.

Indexed as

antibioticantibiotic resistancebiosensorimmunoassaypoint-of-care testingtherapeutic drug monitoringVancomycin

Identifiers

PMID42473667
PMCPMC13380757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.